Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response…

Overview of attention for article published in BMC Neurology, April 2008

Altmetric Badge

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 26 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Management of Relapsing-Remitting Multiple Sclerosis

Cited by Canadian Agency for Drugs and Technologies in Health on 18 Mar 2014

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.